Wednesday, January 18, 2017

BRIEF-Final CIMZIA Phase 3 trial meets primary efficacy endpoint

* Final CIMZIA (Certolizumab Pegol) phase 3 trial meets

primary efficacy endpoint in patients with moderate-to-severe

chronic Plaque Psoriasis

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)